Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recommendations for medical management of hereditary breast and ovarian cancer: The INSERM-FNCLCC ad hoc committee
Autore:
Eisinger, F; Alby, N; Bremond, A; Dauplat, J; Espie, M; Janiaud, P; Kuttenn, F; Lebrun, JP; Lefranc, JP; Pierret, J; Sobol, H; Stoppa-Lyonnet, D; Thouvenin, D; Tristant, H; Feingold, J;
Indirizzi:
Inst J Paoli I Calmettes, INSERM, CRI 9703, F-13009 Marseille, France InstJ Paoli I Calmettes Marseille France F-13009 3009 Marseille, France Ligue Natl Canc, Paris, France Ligue Natl Canc Paris FranceLigue Natl Canc, Paris, France Univ Ctr Leon Berard, Lyon, France Univ Ctr Leon Berard Lyon FranceUniv Ctr Leon Berard, Lyon, France CRLCC Clermont Jean Perrin, Clermont Ferrand, France CRLCC Clermont Jean Perrin Clermont Ferrand France mont Ferrand, France Hop St Louis, Paris, France Hop St Louis Paris FranceHop St Louis, Paris, France INSERM, SC 15, F-75654 Paris 13, France INSERM Paris France 13INSERM, SC 15, F-75654 Paris 13, France Hop Necker Enfants Malad, Paris, France Hop Necker Enfants Malad Paris France cker Enfants Malad, Paris, France Hop La Pitie Salpetriere, Paris, France Hop La Pitie Salpetriere Paris France Pitie Salpetriere, Paris, France CNRS, Unite 304, INSERM, Paris, France CNRS Paris FranceCNRS, Unite 304, INSERM, Paris, France INSERM, CRI 9703, F-13258 Marseille, France INSERM Marseille France F-13258 ERM, CRI 9703, F-13258 Marseille, France Inst Curie, Paris, France Inst Curie Paris FranceInst Curie, Paris, France Univ Paris 07, Ctr Etud Vivant, Paris, France Univ Paris 07 Paris France niv Paris 07, Ctr Etud Vivant, Paris, France INSERM, U155, Paris, France INSERM Paris FranceINSERM, U155, Paris, France
Titolo Testata:
ANNALES D ENDOCRINOLOGIE
fascicolo: 6, volume: 59, anno: 1998,
pagine: 470 - 484
SICI:
0003-4266(1998)59:6<470:RFMMOH>2.0.ZU;2-0
Fonte:
ISI
Lingua:
FRE
Soggetto:
SUSCEPTIBILITY GENE; BRCA1 MUTATIONS; FAMILY HISTORY; FOLLOW-UP; WOMEN; RISK; LINE; INFORMATION; MAMMOGRAPHY; GUIDELINES;
Keywords:
BRCA1; BRCA2; breast cancer; guidelines; ovarian cancer; preventive care;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
56
Recensione:
Indirizzi per estratti:
Indirizzo: Eisinger, F InstMarseille, Calmettes, INSERM, CRI 9703, 232 Bd Ste Marguerite, F-13009 Inst J Paoli I Calmettes 232 Bd Ste Marguerite Marseille France F-13009
Citazione:
F. Eisinger et al., "Recommendations for medical management of hereditary breast and ovarian cancer: The INSERM-FNCLCC ad hoc committee", ANN ENDOCR, 59(6), 1998, pp. 470-484

Abstract

Background : Almost 10% of breast and ovarian cancer are inherited and themajority are linked to BRCA1 and BRCA2 germline mutations. Despite the uncertainty, consensus guidelines were defined to assist practitioners', and patients decisions about the health care decisions to be made. Methodology: The Ad Hoc Committee consisted of 14 experts designated by the French National Institute Sor Health and Medical Research. They all attended eleven workshops at which a systematic analytical review of more than 3500 articles was carried out. Five additional experts critically analyzed the first version of the report. Process : Two thresholds were defined on a probability scale giving the risk of developing breast or ovarian cancer; to serve as a means of deciding as whether an intervention is worthwhile. The first threshold is that above which an intervention carr be envisaged or recommended; the second is that under which an intervention cart be ruled out; between the two, the decision has to be made on a each by case basis. Screening and preventive strategies Analysed: about breast cancer : 1) hormonal interventions; 2) primary prevention (diet, family planning and chemoprevention); 3) screening (breast self-examination, clinician breast examination, tumor markers, imaging); (4 prophylactic mastectomy. About ovarian cancer: 1) hormonal stimulation; 2) screening (clinical screening ultrasound and tumor markers); 3) prophylactic oophorectomy. Main conclusion: With each strategy the following points were dealt with :the information to be delivered to the consult and, the procedure and the indictions. The committee's opinion about BRCA mutation screening is the population-based or even large scale implementation are not justified. The Committee feels that specific management is indispensable and advocates the use of defined and evaluated procedures, and involvement in clinical trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 23:07:21